Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that develops and commercializes prescription medicines for neurological, sleep, psychiatric, and other specialty disease areas. Its portfolio includes marketed products such as Fanapt, HETLIOZ, PONVORY, and NERES, alongside a pipeline of additional indications and new drug candidates.

−69,4 %

−102,0 %

+8,7 %

2.39

2.38

— Vanda Pharmaceuticals Inc.
%
Commercial products85% Approved prescription medicines sold in the U.S. and select international markets.
Sleep and circadian disorders35% HETLIOZ-based therapies for Non-24, SMS, and related sleep indications.
Psychiatry25% Fanapt and related programs for schizophrenia, bipolar disorder, and depression.
Neurology and immunology20% PONVORY and pipeline assets for multiple sclerosis and inflammatory diseases.
Pipeline and partnered development15% Earlier-stage candidates across rare disease, GI, dermatology, and oncology.

Vanda sells primarily to a limited number of U.S. pharmaceutical wholesalers, specialty pharmacies, and specialty...

  • U.S. pharmaceutical wholesalersprimary

    Buy Fanapt and other products for broad downstream distribution in the retail channel.

  • Specialty pharmaciesprimary

    Dispense HETLIOZ and other specialty medicines to patients under restricted distribution.

  • Specialty distributorsprimary

    Handle PONVORY fulfillment and inventory flow in the specialty prescription channel.

  • International commercial partnerssecondary

    Distribute selected products such as Fanapt in Israel and HETLIOZ in Germany.

  • Patients and prescribersprimary

    End users and decision makers whose diagnosis, prescribing, and adherence drive demand.

Vanda is headquartered in Washington, D.C. and commercializes its products primarily in the United States...

  • •Headquartered in Washington, D.C.
  • •Primary commercial market is the United States
  • •Fanapt is distributed in Israel through a partner
  • •HETLIOZ is sold in Germany
  • •International revenue is limited versus U.S. sales

Vanda’s strategy centers on maximizing the commercial performance of its marketed products while expanding them into...

01
Defend and grow the commercial portfolioshort-term

Current products fund the business and support the company’s commercial infrastructure.

02
Expand label breadth for existing productsmedium-term

Additional indications can extend product life cycles and broaden addressable markets.

03
Build a differentiated pipelinemedium-term

New molecular assets reduce dependence on a small number of marketed products.

Vanda depends on a small number of commercial products and a concentrated set of customers, so sales can be volatile...

high

Generic competition for HETLIOZ and other products

Loss of exclusivity can materially reduce U.S. sales and market share.

Scope
HETLIOZ
Materiality
high
high

Customer concentration

A limited number of wholesalers and specialty pharmacies can drive quarter-to-quarter volatility.

Scope
Fanapt, HETLIOZ, PONVORY
Materiality
high
high

Patent and IP litigation

Enforcement and defense of patents consume resources and may not preserve exclusivity.

Scope
HETLIOZ and other branded products
Materiality
high
medium

Regulatory and clinical development risk

Pipeline programs may fail in trials or be delayed by regulators.

Scope
Bysanti, imsidolimab, VTR-297, ASO programs
Materiality
high
medium

Reimbursement and pricing pressure

Specialty drug demand depends on payor coverage and favorable reimbursement.

Scope
U.S. commercial portfolio
Materiality
high
Revenue allowances and variable consideration
Can materially affect quarterly revenue and gross-to-net trends
Point-in-time revenue recognition
Timing of wholesaler and specialty pharmacy orders affects period results
Accounts receivable and credit loss estimates
Bad-debt assumptions can move operating results
Deferred tax asset valuation allowance
Can create large non-cash swings in reported tax expense
Contingent milestone and license obligations
Affects liabilities and operating cash flow timing

ANAPTYSBIO, INC

ANAB · Pharmaceutical Preparations

Verrica Pharmaceuticals Inc.

VRCA · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

Edesa Biotech, Inc.

EDSA · Pharmaceutical Preparations

Sedana Medical

SEDANA.ST · Health Care

ENDRA Life Sciences Inc.

NDRA · Electromedical & Electrotherapeutic Apparatus

: 29.4.2026